CDK inhibitor Palbociclib targets STING to alleviate autoinflammation

ABSTRACT: Aberrant activation of stimulator of interferon genes (STING) is tightly associated with multiple types of disease, including cancer, infection and autoimmune diseases. However, the development of STING modulators for the therapy of STING-related diseases is still an unmet need. We employed a high throughput screening approach based on the interaction of small molecule chemical compounds with recombinant STING protein to identify functional STING modulators. Intriguingly, the cyclin-dependent protein kinases (CDKs) inhibitor Palbociclib was found to directly bind STING and inhibit its activation in both mouse and human cells. Mechanistically, Palbociclib targets Y167 of STING to block its dimerization, its binding with cyclic dinucleotides and its trafficking. Importantly, Palbociclib alleviates autoimmune disease features induced by dextran sulphate sodium or genetic ablation of three prime repair exonuclease 1 (Trex1) in mice in a STING-dependent manner. Our work identifies Palbociclib as a novel pharmacological inhibitor of STING that abrogates its homodimerization and provides a basis for the fast repurposing of this Food and Drug Administration-approved drug for the therapy of autoinflammatory diseases.

SUBMITTER: Dr. Jiani Gao 

PROVIDER: S-SCDT-EMBOR-2021-53932V1 | biostudies-other |

REPOSITORIES: biostudies-other